Hepatotoxicity associated with anti-neoplastic agents: a pharmacovigilance analysis of the Food and Drug Administration Adverse Event Reporting System database. [PDF]
Shi L, Wang Y, Qu Y, Chen R.
europepmc +1 more source
Trust but Verify: Lessons Learned for the Application of AI to Case-Based Clinical Decision-Making From Postmarketing Drug Safety Assessment at the US Food and Drug Administration [PDF]
Robert Ball +4 more
openalex +1 more source
The Food and Drug Administration as Gatekeeper and the Menthol Exemption
Micah L. Berman, Desmond Jenson
openalex +2 more sources
Comment on “High-Sensitivity C-Reactive Protein: Product Claims and the Food and Drug Administration” [PDF]
Marva Moxey‐Mims
openalex +1 more source
Unleashing the Power of Machine Learning in Nanomedicine Formulation Development
A random forest machine learning model is able to make predictions on nanoparticle attributes of different nanomedicines (i.e. lipid nanoparticles, liposomes, or PLGA nanoparticles) based on microfluidic formulation parameters. Machine learning models are based on a database of nanoparticle formulations, and models are able to generate unique solutions
Thomas L. Moore +7 more
wiley +1 more source
A real-world disproportionality analysis of roflumilast using the US food and drug administration adverse event reporting system data. [PDF]
Huang B, Ma Y, Wang W, Gu S, Wang X.
europepmc +1 more source
Evaluating cardiac disorders associated with triazole antifungal agents based on the US Food and Drug Administration Adverse Event reporting system database [PDF]
Jinhua Chen +4 more
openalex +1 more source
Light‐Responsive Enzyme‐Loaded Nanoparticles for Tunable Adhesion and Mechanical Wound Contraction
This study presents a photoactivatable enzyme‐loaded mesoporous nanoparticle system (MPDA_PaTy) that enables light‐triggered tunable tissue adhesion and facilitates mechanical wound contraction. Controlled enzymatic crosslinking at tissue or hydrogel interfaces allows on‐demand adhesion.
Junghyeon Ko +10 more
wiley +1 more source
Letter from Joshua Lederberg to John B. Robbins, U. S. Food and Drug Administration
Joshua Lederberg
openalex +1 more source

